Feed GMED
GM

Globus Medical GMED NYSE · Healthcare · United States

$68.57 -2.77% -$1.96

Summary

83 / 100 · Bulios Score

What speaks for it

  • Earnings per share grew by 28% a year over the last 3 years.
  • Out of every 100 USD of revenue, 18 USD is left as net profit.
  • It holds more cash than debt: $441.3M against $107.6M.
  • The share price is below the Bulios Fair Price.

What to watch

  • Earnings per share swing sharply from year to year.

Bulios Scoring describes a company's quality and track record, not its future return. A high score is not a buy signal. Learn more

Score in detail

Price

Is it expensive?

Looks cheap
Bulios Fair Price
Undervalued Price today $68.57

By our assumptions the business is worth more than its shares cost today.

P/E today 16.3 70% lower
5-year average P/E 54.6
P/E today 16.3
Medical - Devices industry median

Bulios Fair Price is an estimate of a stock's fair value from the Bulios valuation model. It is an input for your own analysis, not investment advice. How does it work?

Today you pay 16.3 USD for 1 USD of yearly profit. Over the last five years it was 54.6 USD on average.

Valuation in detail

Is it growing?

Yes, fast

Revenue (USD)

Diluted EPS (USD)

  • Analyst estimate

Revenue grew by 30% a year over 5 years. Over the last 3 years it grew by 42% a year. For the next fiscal year analysts expect revenue to grow by 5.5%. Earnings per share grew by 28% a year over the last 3 years.

Growth in detail

Does it make money?

Very well

Where 100 USD of revenue goes

Net profit, industry median (Medical - Devices) 7.2 USD

Out of every 100 USD of revenue, 18 USD is left as net profit.

Profitability in detail

Is it financially healthy?

Yes

It could repay all its debt from a single year of free cash flow. It holds more cash than debt.

Financial health in detail

Does it pay a dividend?

No

It pays no dividend.

Dividends in detail

What do analysts expect?

Mildly positive

Today's price within the analysts' price targets

The average target of $95.13 is 39% above today's price. 70% of the analysts recommend buying.

Analysts in detail

What does it earn on?

Fiscal year 2024

By product

By region

Spine brings in 94% of revenue. Emerging Technology grew fastest, by 40% a year.

Segments in detail

We use essential cookies to run the website and optional analytics cookies to measure usage.

Privacy policy